Ethic Inc. Buys 3,353 Shares of Repligen Corporation $RGEN

Key Points

• Ethic Inc. significantly increased its holdings in Repligen Corporation by 195.9% during the first quarter, owning 5,065 shares valued at approximately $651,000.
• Repligen's stock has seen a decline of 1.6%, with a current price of $121.56, while the company reported a 14.8% increase in quarterly revenue compared to the same period last year.
• Several analysts have altered their price targets for Repligen, with Evercore ISI and JPMorgan Chase & Co. both lowering their targets to $130.00 and $190.00, respectively.

Ethic Inc. increased its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 195.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,065 shares of the biotechnology company's stock after buying an additional 3,353 shares during the quarter. Ethic Inc.'s holdings in Repligen were worth $651,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Utah Retirement Systems lifted its position in shares of Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 100 shares during the period. State of Michigan Retirement System lifted its position in shares of Repligen by 0.8% during the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after buying an additional 100 shares during the period. Louisiana State Employees Retirement System lifted its position in shares of Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after buying an additional 100 shares during the period. Signaturefd LLC lifted its position in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares during the period. Finally, Commerce Bank increased its holdings in Repligen by 7.5% during the 1st quarter. Commerce Bank now owns 1,899 shares of the biotechnology company's stock valued at $242,000 after purchasing an additional 133 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Activity

In related news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.20% of the stock is owned by corporate insiders.

Repligen Trading Up 4.3%

Shares of NASDAQ RGEN traded up $5.14 during midday trading on Friday, hitting $124.79. The stock had a trading volume of 775,437 shares, compared to its average volume of 898,905. The company's 50-day simple moving average is $121.66 and its 200 day simple moving average is $131.33. The firm has a market cap of $7.02 billion, a P/E ratio of -499.14, a price-to-earnings-growth ratio of 2.30 and a beta of 1.05. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period last year, the business posted $0.40 earnings per share. The firm's quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RGEN shares. Wells Fargo & Company dropped their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Barclays started coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target for the company. Evercore ISI dropped their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Finally, Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.